The evolving science of pharmacogenetics: Clinical and ethnic perspectives

Psychopharmacology Bulletin

Volumn 32, Issue 2, 1996, Pages 205-217

  Lin, Keh Ming ^a   Poland, Russell E ^a   Wan, Yu Jui Y ^a   Smith, Michael W ^a   Lesser, Ira M ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

ethnicity; metabolism; P450; pharmacogenetics; psychotropics

Indexed keywords

CYTOCHROME P450 ISOENZYME; PSYCHOTROPIC AGENT;

ADDICTION; ARTICLE; BIOTRANSFORMATION; BRAIN FUNCTION; CLINICAL RESEARCH; CULTURAL FACTOR; DISEASE PREDISPOSITION; DRUG METABOLISM; ENZYME INHIBITION; ETHNIC GROUP; HUMAN; NEUROTOXICITY; PARKINSON DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; EVALUATION STUDIES; HUMANS; PHARMACOGENETICS;

EID: 0029779695     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. Agundez, JA; Ledesma, MC; Ladero, JM; and Benitez, J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 57:265-269, 1995.
2. Agundez, JA; Martinez, C; Ledesma, MC; Ladona, MG; Ladero, JM; and Benitez, J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin. Pharmacol. Ther. 55:412-417, 1994.
3. Allen, J; Rack, P; and Vaddadi, K. Differences in the effects of clomipramine on English and Asian volunteers: Preliminary report on a pilot study. Postgrad. Med. J. 53:79-86, 1977.
4. Alvan, G. Clinical consequences of polymorphic drug oxidation. Fundam. Clin. Pharmacol. 5:209-228, 1991.
5. Anderson, KE. Influences of diet and nutrition on clinical pharmacokinetics. Clin. Pharmacokinet. 14:325-346, 1988.
6. Anderson, KE, and Kappas, A. Dietary regulation of cytochrome P450. Annu. Rev. Nutr. 11:141-167, 1991.
7. Aranow, RB; Hudson, JI; Pope, HG; Grady, TA; Laage, TA; Bell, IR; and Cole, JO. Elevated antidepressant plasma levels after addition of fluoxetine. Am. J. Psychiatry 146:911-913, 1989.
8. Arias, TD; Inaba, T; Cooke, RG; and Jorge, LF. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbe Guaymi Amerindians: A case of genetic divergence with tentative phylogenetic time frame for the pathway. Clin. Pharmacol. Ther. 44:343-352, 1988a.
9. Arias, TD; Jorge, LF; Lee, D; Barrantes, R; and Inaba, T. The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: Absence of evidence for deficient metabolizers. Clin. Pharmacol. Ther. 43:456-465, 1988b.
10. Arthur, H; Dahl, ML; Siwers, B; and Sjoqvist, F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol. 15:211-216, 1995.
11. Baer, AN; McAllister, CB; Wilkinson, GR; Woolsley, RL; and Pincus, T. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum. 29:843-850, 1986.
12. Benitez, J; Ladero, JM; Fernandez-Gundin, MJ; Llerena, A; Cobaleda, J; Martinez, C; Munoz, JJ; Vargas, E; Prados, J; and Gonzalez-Rozas, F. Polymorphic oxidation of debrisoquine in bladder cancer. Ann. Med. 22:157-160, 1990a.
13. Benitez, J; Ladero, JM; Jimenez-Jimenez, FJ; Martinez, C; Puerto, AM; Valdivielso, MJ; Llerena, A; Cobaleda, J; and Munoz, JJ. Oxidative polymorphism of debrisoquine in Parkinson's disease. J. Neural. Neurosurg. Psychiatry 53:289-292, 1990b.
14. Benitez, J; Ladero, JM; Jara, C; Carrillo, JA; Cobaleda, J; Llerena, A; Vargas, E; and Munoz, JJ. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur. J. Cancer 27:158-161, 1991.
15. Bergstrom, RF; Peyton, AL; and Lemberger, L. Qualification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther. 51:239-248, 1992.
16. Bertilsson, L; Alm, C; and DeLas, C. Debrisoquine hydroxylation polymorphism and personality. Lancet 1:555, 1989.
17. Bertilsson, L; Dahl, ML; Sjoqvist, F; Aberg-Wistedt, A; Humble, M; Johansson, I; Lundqvist, E; and Ingelman-Sundberg, M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter] [see comments]. Lancet 341:63, 1993.
18. Bertilsson, L; Lou, Y; Du, Y; Liao, Z; Wang, K; Reviriego, J; Iselius, L; and Sjoqvist, F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin. Pharmacol. Ther. 51:388-397, 1992.
19. Bertschy, G; Vandel, S; Vandel, B; Allers, G; and Volmat, R. Fluvoxamine tricyclic antidepressant interaction. An accidental finding. Eur. J. Clin. Pharmacol. 40:119-120, 1991.
20. Bluhm, RE; Wilkinson, GR; Shelton, R; and Branch, RA. Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: A case report. Clin. Pharmacol. Ther. 1:89-95, 1993.
21. Brosen, K; Gram, LF; Klysner, R; and Bech, P. Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics. Eur. J. Clin. Pharmacol. 30:43-49, 1986.
22. Brosen, K, and Kragh-Sorensen, P. Concomitant intake of nortriptyline and carbamazepine. Ther. Drug Monit. 15:258-260, 1993.
23. Brosen, K; Sindrup, SH; Nielsen, KK; Norremark, P; and Gram, LF. Role of genetic polymorphism in psychopharmacology - An update. In: Dahl, SG, and Gram, LF, eds. Clinical Pharmacology in Psychiatry. Berlin, Germany: Springer-Verlag, 1992.
24. Brosen, K; Zeugin, T; and Meyer, UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 49:609-617, 1991.
25. Brosen, K; Zeugin, T; Meyer, UA; Sindrup, SH; and Gram, LF. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther. Drug Monit. 12:445-449, 1990.
26. Butler, MA; Lang, NP; Young, JF; Caporaso, NE; Vineis, P; Hayes, RB; Teitel, CH; Massengill, JP; Lawsen, MF; and Kadlubar, FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127, 1992.
27. Caporaso, N; Landi, MT; and Vineis, P. Relevance of metabolic polymorphisms to human carcinogenesis: Evaluation of epidemiologic evidence. Pharmacogenetics 1:4-19, 1991.
28. Caporaso, NE; Shields, PG; Landi, MT; Shaw, GL; Tucker, MA; Hoover, R; Sugimura, H; Weston, A; and Harris, CC. The debrisoquine metabolic phenotype and DNA-based assays: Implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ. Health Perspect. 98:101-105, 1992.
29. Caporaso, N; Whitehouse, J; Monkman, S; Boustead, C; Issaq, H; Fox, S; Morse, MA; Idle, JR; and Chung, FL. In vitro but not in vivo inhibition of CYP2D6 by phenethyl isothiocyanate (PEITC), a constituent of watercress. Pharmacogenetics 4:275-280, 1994.
30. Chen, ZR; Somogyi, AA; and Bochner, F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high performance liquid chromatography with application to their disposition in man. Ther. Drug Monit. 12:97-104, 1990.
31. Cholerton, S; Daly, A; and Idle, J. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13:434-439, 1992.
32. Ciraulo, DA; and Shader, RI. Fluoxetine drug-drug interactions. I. Antidepressants and antipsychotics. J. Clin. Psychopharmacol. 10:48-50, 1990.
33. Coutts, RT. Polymorphism in the metabolism of drugs, including antidepressant drugs: Comments on phenotyping. J. Psychiatry Neurosci. 19:30-44, 1994.
34. Dahl, ML; Johansson, I; Palmertz, MP; Ingelman-Sundberg, M; and Sjoqvist, F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther. 51:12-17, 1992.
35. DeVane, CL. Pharmacokinetics of the newer antidepressants: Clinical relevance. Am. J. Med. 97:13S-23S, 1994.
36. Dollery, C; Fraser, H; and Mucklow, J. Contribution of environmental factors to variability in human drug metabolism. Drug Metab. Rev. 9:207-220, 1979.
37. Eichelbaum, M, and Gross, AS. The genetic polymorphism of debrisoquine/sparteine metabolism-Clinical aspects. Pharmacol. Ther. 46:377-394, 1990.
38. Eichelbaum, M, and Woolhouse, NM. Inter-ethnic differences in sparteine oxidation among Ghanaians and Germans. Eur. J. Clin. Pharmacol. 28:79-83, 1985.
39. Evans, WE; Relling, MV; Rahman, A; McLeod, HL; Scott, EP; and Lin, JS. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J. Clin. Invest. 91:2150-2154, 1993.
40. Fraser, H; Mucklow, J; Bulpitt, C; Kahn, C; Mould, G; and Dollery, C. Environmental factors affecting antipyrine metabolism in London factory and office workers. Br. J. Clin. Pharmacol. 7:237-243, 1979.
41. Gonzalez, F. The molecular biology of cytochrome P450s. Pharmacol. Rev. 40:243-288, 1989.
42. Gonzalez, FJ. Human cytochromes P450: Problems and prospects. Trends Pharmacol. Sci. 13:346-352, 1992.
43. Gonzalez, FJ, and Nebert, DW. Evolution of the P450 gene superfamily: Animal-plant "warfare," molecular drive and human genetic differences in drug oxidation. Trends Genet. 6:182-186, 1990.
44. Gram, LF, and Fredricson-Overo, K. Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br. Med. J. 1:463-465, 1972.
45. Greenblatt, D. Basic pharmacokinetic principles and their application to psychotropic drugs. J. Clin. Psychiatry [Suppl.] 54:8-13, 1993.
46. Guengerich, FP, and Kim, DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11:2275-2279, 1990.
47. Heim, M, and Meyer, UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532, 1990.
48. Heim, MH, and Meyer, UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14:49-58, 1992.
49. Hirschowitz, J; Bennet, JA; Zemlan, FP; and Garver, DL. Thioridazine effect on desipramine plasma levels. J. Clin. Pharmacol. 3:376-379, 1983.
50. Ingelman-Sundberg, M; Johansson, I; Persson, I; Oscarson, M; Hu, Y; Bertilsson, L; Dahl, ML; and Sjoqvist, F. Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity. EXS. 71:197-207, 1994.
51. Iwahashi, K. CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol. Psychiatry 36:780-782, 1994.
52. Iyun, AO; Lennard, MS; Tucker, GT; and Woods, HF. Metoprolol and debrisoquin metabolism in Nigerians: Lack of evidence for polymorphic oxidation. Clin. Pharmacol. Ther. 40:387-394, 1986.
53. Johansson, I; Lundqvist, E; Bertilsson, L; Dahl, ML; Sjoqvist, F; and Ingelman-Sundberg, M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine [see comments]. Proc. Natl. Acad. Sci. U. S. A. 90:11825-11829, 1993.
54. Kaisary, A; Smith, P; Jaczq, E; McAllister, CB; Wilkinson, GR; Ray, WA; and Branch, RA. Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 47:5488-5493, 1987.
55. Kalow, W. Pharmacogenetics: Past and future. Life Sci. 47:1385-1397, 1990.
56. Kalow, W. Interethnic variation of drug metabolism. Trends Pharmacol. Sci. 12:102-107, 1991.
57. Kalow, W. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press, 1992.
58. Kalow, W. Pharmacogenetics: Its biologic roots and the medical challenge. Clin. Pharmacol Ther. 54:235-241, 1993.
59. Kalow, W, and Tang, B. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoke. Clin. Pharmacol. Ther. 49:44-48, 1991a.
60. Kalow, W, and Tang, BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. Ther. 50:508-519, 1991b.
61. Kalow, W, and Tyndale, RF. Debrisoquine/sparteine monooxygenase and other P-450s in brain. In: Kalow, W, ed. Pharmacogenetics of Drug Metabolism: International Encyclopedia of Pharmacology and Therapeutics. New York: Pergamon Press, 1992. pp. 649-656.
62. Kigimoto, M; Heim, M; Kaimoto, K; Zeugin, T; and Meyer, UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J. Biol. Chem. 265:17209-17214, 1990.
63. Kim, RB; O'Shea, D; and Wilkinson, GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther. 57:645-655, 1995.
64. Lennard, MS. Genetic polymorphism of sparteine/debrisoquine oxidation: A reappraisal. Pharmacol. Toxicol. 67:273-283, 1990.
65. Lennard, MS; Iyun, AO; Jackson, PR; Tucker, GT; and Woods, HF. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2:89-92, 1992.
66. Lennard, MS; Tucker, GT; Woods, HF; Iyun, AO; and Eichelbaum, M. Stereoselective 4-hydroxylation of debrisoquine in Nigerians. Biochem. Pharmacol. 37:97-98, 1988.
67. Lennard, MS; Tucker, GT; Woods, HF; Silas, JH; and Iyun, AO. Stereoselective metabolism of metoprolol in Caucasians and Nigerians-Relationship to debrisoquine oxidation phenotype. Br. J. Clin. Pharmacol. 27:613-616, 1989.
68. Lewis, P; Rack, P; and Vaddadi, K. Ethnic differences in drug response. Postgrad. Med. J. 56(Suppl. 1):46-49, 1980.
69. Lin, KM, and Poland, RE. Ethnicity, culture, and psychopharmacology. In: Bloom, FE, and Kupfer, DI, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995. pp. 1907-1919.
70. Lin, KM; Poland, RE; and Nakasaki, G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington, DC: American Psychiatric Press, 1993.
71. Llerena, A; Edman, G; Cobaleda, J; Benitez, J; Schalling, D; and Bertilsson, L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87:23-28, 1993a.
72. Llerena, A; Herraiz, AG; Cobaleda, J; Johansson, I; and Dahl, ML. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Ther. 54:606-611, 1993b.
73. London, SJ; Daly, AK; Thomas, DC; Caporaso, NE; and Idle, JR. Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk [letter]. Pharmacogenetics 4:107-108, 1994.
74. Lou, YC; Liu, Y; Bertilsson, L; and Sjoqvist, F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2:852-853, 1987.
75. Masimirembwa, CM; Bertilsson, L; Johansson, I; Hasler, J; and Ingelman-Sundberg, M. "Diminished Enzyme Activity and Lack of Metabolic Coregulation of CYP2D6 Probe Drugs in a Black Zimbabwean (Shona) Population." Presented at Pharmacogenetics: Optimize Drug Discovery & Development meeting, May 1995, Bethesda, MD.
76. Masimirembwa, CM; Johansson, I; Hasler, JAL; and Ingelman-Sundberg, M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 3:275-280, 1993.
77. Meyer, UA. Molecular genetics and the future of pharmacogenetics. In: Kalow, W, ed. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press, 1992. pp. 879-888.
78. Meyer, UA. Pharmacogenetics: The slow, the rapid, and the ultrarapid. Proc. Natl. Acad. Sci. U. S. A. 91:1983-1984, 1994.
79. Meyer, UA; Zanger, RM; Grant, D; and Blum, M. Genetic polymorphisms of drug metabolism. Adv. Drug Res. 19:197-241, 1990.
80. Miller, LG. Cigarettes and drug therapy: Pharmacokinetic and pharmacodynamic considerations. Clin. Pharm. 9:125-135, 1990.
81. Morimoto, M; Hagb-Jork, AL; Wan, YJY; Fu, PC; Clot, P; Albano, E; Ingleman-Sundberg, M; and French, SW. Modulation of experimental alcohol-induced liver disease by cytochrome P450 2E1 inhibitors. Hepatology 21:1610-1617, 1995.
82. Mortimer, O; Persson, K; Ladona, MG; Spalding, D; Zanger, UM; Meyer, UA; and Rane, A. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P-450IID1. Clin. Pharmacol. Ther. 47:27-35, 1990.
83. Murray, M. P450 enzymes - inhibition mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokinet. 23:132-146, 1992.
84. Murray, M, and Reidy, G. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 42:85-101, 1990.
85. Nebert, DW; Nelson, DR; Coon, MJ; Estabrook, RW; Feyereisen, R; Fujii-Kuriyama, Y; Gonzalez, FJ; Guengerich, FP; Gunsalus, IC; and Johnson, EF. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 10(1): 1-14, 1991. [Published erratum appears in DNA Cell Biol. 10(5):397-398, 1991.]
86. Nebert, DW, and Weber, WW. Pharmacogenetics. In: Pratt, WB, and Taylor, P, eds. Principles of Drug Action. New York: Churchill Livinston, 1990. pp. 469-531.
87. Niznik, HB; Tyndale, RF; Sallee, FR; Gonzalez, FJ; Hardwick, JP; Inaba, T; and Kalow, W. The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: Resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch. Biochem. Biophys. 276:424-432, 1990.
88. Okey, A. Enzyme induction in the cytochrome P-450 system. In: Kalow, W, ed. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press, 1992.
89. Polednak, A. Racial & Ethnic Differences in Disease. New York: Oxford University Press, 1989.
90. Preskorn, SH. Antidepressant drug selection: Criteria and options. J. Clin. Psychiatry 55 (Suppl. A):6-24, 1994.
91. Relling, MV; Cherrie, J; Schell, MJ; Petros, WP; Meyer, WH; and Evans, WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin. Pharmacol. Ther. 50:308-313, 1991.
92. Roots, I; Drakoulis, D; and Brockmoller, J. Polymorphic enzymes and cancer risk: Concepts, methodology and data review. In: Kalow, W, ed. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press, 1992. pp. 815-841.
93. Rudorfer, MV. Pharmacokinetics of psychotropic drugs in special populations. J. Clin. Psychiatry 54 (Suppl.):50-54, 1993.
94. Sellers, EM; Otton, V; Tyndale, RF; Sproule, BA; Israel, Y; Zawertailo, L; Somer, G; and Gorthy, L. "Under-representation of Cytochrome P450 2D6 (CYP2D6) Deficient Genotype in Drug Dependence: Initial Results." Presented at Fifty-Seventh Annual Scientific Meeting, College on Problems of Drug Dependence, Scottsdate, AZ, 1995. p. 127.
95. Sellers, EM; Otton, SV; and Tyndale, RF. Pharmacogenetics of human cytochrome P450 2D6 (CYP2D6): Implications for substance abuse and other disorders. Abstracts of Panels and Posters, p. 69. Presented at the 33rd Annual Meeting of the American College of Neuropsychopharmacology, December 1994.
96. Setiabudy, R; Kusaka, M; Chiba, K; Darmansjah, I; and Ishizaki, T. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: A cocktail and extended phenotyping assessment trial. Clin. Pharmacol. Ther. 56:142-153, 1994.
97. Shinn, AF. Clinical relevance of cimetidine drug interactions. Drug Saf. 7:245-267, 1992.
98. Silver, B; Lin, KM; and Poland, RE. Ethnicity and the pharmacology of tricyclic antidepressants. In: Lin, KM; Poland, RE; and Nakasaki, G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington, DC: American Psychiatric Press, 1993. pp. 61-91.
99. Sindrup, SH; Arendt-Nielsen, L; Brosen, K; Bjerring, P; Angelo, HR; Eriksen, B; and Gram, LF. The effect of quinidine on the analgesic effect of codeine. Eur. J. Clin. Pharmacol. 42:587-591, 1992.
100. Sindrup, SH; Brosen, K; and Gram, LF. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther. Drug Monit. 12:445-449, 1990.
101. Sindrup, SH; Poulsen, L; Brosen, K; Arendt-Nielsen, L; and Gram, LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 53:335-339, 1993.
102. Skjelbo, E, and Brosen, K. Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34:256-261, 1992.
103. Skoda, RC; Gonzalez, FJ; Demierre, A; and Meyer, UA. Two mutant alleles of the human cytochrome P450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. U. S. A. 85:5240-5243, 1988.
104. Sommers, DK; Moncrieff, J; and Avenant, J. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa. Hum. Toxicol. 7:273-276, 1988.
105. Sommers, DK; Moncrieff, J; and Avenant, J. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum. Toxicol. 8:365-368, 1989.
106. Tucker, GT; Lennard, MS; Ellis, SW; Woods, HF; Cho, AK; Lin, LY; Hiratsuka, A; Schmitz, DA; and Chu, TY. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47:1151-1156, 1994.
107. Tyndale, RF; Sunahara, R; Inaba, T; Kalow, W; Gonzalez, FJ; and Niznik, HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol. Pharmacol. 40:63-68, 1991.
108. Vesell, ES. Genetic and environmental factors causing variation in drug response [review]. Mutat. Res. 247:241-257, 1991.
109. Wang, T; Roden, DM; Wolfenden, HT; Woosley, RL; Wood, AJJ; and Wilkinson, GR. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J. Pharmacol. Exp. Ther. 228:605-611, 1984.
110. Weber, WW. The Acetylator Genes and Drug Responses. New York: Oxford University Press, 1987.
111. Woolhouse, NM; Andoh, B; Mahgoub, A; Sloan, TP; Idle, JR; and Smith, RL. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin. Pharmacol. Ther. 26:584-591, 1979.
112. Woolhouse, NM; Eichelbaum, M; Oates, NS; Idle, JR; and Smith, RL. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin. Pharmacol. Ther. 37:512-521, 1985.
113. Yee, GC; Stanley, DL; Pessa, LJ; Dalla Costa, T; Beltz, SE; Ruiz, J; and Lowenthal, DT. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 345:955-956, 1995.
114. Yokota, H; Tamura, S; Furuya, H; and Kimura, S. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3:256-263, 1993.
115. Yoo, JS; Park, HS; Ning, SM; Lee, MJ; and Yang, CS. Effects of thiamine deficiency on hepatic cytochromes P450 and drug-metabolizing enzyme activities. Biochem. Pharmacol. 39:519-525, 1990.
116. Yue, QY; Bertilsson, L; Dahl-Puustinen, ML; Sawe, J; Sjoqvist, F; Johansson, I; and Ingelman-Sundberg, M. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet 2:870, 1989a.
117. Yue, QY; Svensson, JO; Aim, C; Sjoqvist, F; and Sawe, J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine, Br. J. Clin. Pharmacol. 28:629-637, 1989b.
118. Ziegler, V; and Biggs, J. Tricyclic plasma levels - Effect of age, race, sex, and smoking. JAMA 438:2167-2169, 1977.